OncoSec Medical Incorporated is a biotechnology company focused on developing intratumoral cancer immunotherapies. The company’s core technology involves the delivery of plasmid DNA directly into tumors to stimulate the body's immune system to fight cancer. Their lead product candidate, TAVO, is designed to deliver IL-12, a protein that can boost the immune response, directly into tumors. This approach aims to generate a systemic immune response that can target and destroy cancer cells throughout the body. OncoSec primarily serves patients with various types of cancer, including metastatic melanoma, and operates within the oncology sector of the biotech industry. The company generates revenue through partnerships, licensing agreements, and potentially future product sales upon regulatory approval. OncoSec's business model is heavily reliant on clinical trials and regulatory milestones to advance their product candidates towards commercialization.

Keywords: intratumoral, cancer, immunotherapy, plasmid DNA, IL-12, systemic immune response, metastatic melanoma, oncology, biotech, clinical trials.